Targeting of NMDA Receptors in the Treatment of Major Depression
The DOI matches its Crossref record.
Abstract
Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays an important role in the neurobiology and treatment of this disease. Currently, the non-competitive NMDA receptor antagonist ketamine is considered as one of the most attractive candidate drugs in therapy of treatment-resistant depression. A recent study demonstrated ketamine's rapid antidepressant activity in patients with treatment-resistant MDD and bipolar disorder. The response rate for ketamine ranged from 25% to 85% at 24 hours post-infusion and from 14% to 70% at 72 hours post-infusion, with generally mild adverse effects. Based on the role of the NMDA receptor in depression, a number of therapeutic drugs which interact with this receptor have been developed. In this article, we reviewed recent findings concerning the role of glutamatergic signaling in the neurobiology of MDD and potential, novel therapeutic drugs, such as ketamine, memantine, AZD6765, traxoprodil, MK-0657, GLYX-13, NRX-1047, D-cycloserine, sarcosine, all of which target this system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, a variety of NMDA receptor antagonists, including ketamine, have displayed efficacy in treating treatment-resistant depression (51), perhaps by disrupting plasticity in depression-related regions including the vHipp (33).”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [51]
Citations
Cites
Still being checked.
Cited by
The Effects of Psychological Stress on Depression
Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831150507 · Cited by 589
“They play important roles in learning and cognition and are closely associated with depression [57] while NMDA receptor antagonists are attractive drug candidates for refractory depression therapy [58].”
BackgroundIrritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Self-citationEmerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression
Francis, T. C., & Lobo, M. K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.09.007 · Cited by 230
“Interestingly, a variety of NMDA receptor antagonists, including ketamine, have displayed efficacy in treating treatmentresistant depression (51), perhaps by disrupting plasticity in depression-related regions including the vHipp (33).”
BackgroundSlominski, A., Kim, T.-K., Brożyna, A. A., Janjetovic, Z., Brooks, D. L. P., Schwab, L. P., Skobowiat, C., Jóźwicki, W., & Seagroves, T. N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.030 · Cited by 203
Metadata
- Authors
- Dang, Y.-H., Ma, X.-C., Zhang, J.-C., Ren, Q., Wu, J., Gao, C.-G., & Hashimoto, K.
- Affiliations
- Chiba University (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-01-10
- Volume
- 20
- Issue
- 32
- Pages
- 5151-5159
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2158031806
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 13 · 2019: 6 · 2018: 9 · 2017: 8 · 2016: 5 · 2015: 12 · 2014: 4
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- NMDA receptor, major depressive disorder, ketamine, treatment-resistant depression, glutamatergic signaling, memantine, D-cycloserine, sarcosine, rapid antidepressant effects, bipolar disorder, antidepressant drug development
- MeSH terms
- Animals, Antidepressive Agents, Major Depressive Disorder, Drug Resistance, Humans, Ketamine, Time Factors, Receptors, N-Methyl-D-Aspartate, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting of NMDA Receptors in the Treatment of Major Depression. https://app.cochat.ai/papers/10.2174/1381612819666140110120435
- The paper
- Dang, Y.-H., Ma, X.-C., Zhang, J.-C., Ren, Q., Wu, J., Gao, C.-G., & Hashimoto, K. (2014). Targeting of NMDA Receptors in the Treatment of Major Depression. Current Pharmaceutical Design. https://doi.org/10.2174/1381612819666140110120435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.